Abaloparatide followed by alendronate in women ≥80 years with osteoporosis: post hoc analysis of ACTIVExtend

OBJECTIVE: Fracture risk increases with age, but few studies focus on persons ≥80 years. In the ACTIVE trial, treatment with abaloparatide for 18 months reduced osteoporotic fracture risk and increased bone mineral density. These effects were maintained with 24 months alendronate treatment in ACTIVE...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Menopause
Hauptverfasser: Greenspan, Susan L., Fitzpatrick, Lorraine A., Mitlak, Bruce, Wang, Yamei, Harvey, Nicholas C., Deal, Chad, Cosman, Felicia, McClung, Michael
Format: Artigo
Sprache:Inglês
Veröffentlicht: Lippincott Williams & Wilkins 2020
Schlagworte:
Original Studies
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7515468/
https://ncbi.nlm.nih.gov/pubmed/32665529
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/GME.0000000000001593
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge